Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Trial details
- Registry ID
- NCT07621718
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Abraxane
| No regulatory events match this view.This does not mean no FDA events have occurred. |